Long-term persistence of zoster vaccine efficacy

Vicki A. Morrison, Gary R. Johnson, Kenneth E. Schmader, Myron J. Levin, Jane H. Zhang, David J. Looney, Robert Betts, Larry Gelb, John C. Guatelli, Ruth Harbecke, Connie Pachucki, Susan Keay, Barbara Menzies, Marie R. Griffin, Carol A. Kauffman, Adriana Marques, John Toney, Kathy Boardman, Shu Chih Su, Xiaoming Li & 53 others Ivan S.F. Chan, Janie Parrino, Paula Annunziato, Michael N. Oxman, L. E. Davis, C. A. Kauffman, S. K. Keay, S. E. Straus, A. R. Marques, N. E. Soto, P. Brunell, J. W. Gnann, R. Serrao, D. J. Cotton, R. P. Goodman, R. D. Arbeit, C. T. Pachucki, M. J. Levin, K. E. Schmader, W. A. Keitel, R. N. Greenberg, V. A. Morrison, P. F. Wright, M. R. Griffin, M. S. Simberkoff, S. S. Yeh, Z. Lobo, M. Holodniy, J. Loutit, R. F. Betts, L. D. Gelb, G. E. Crawford, J. Guatelli, P. A. Brooks, D. J. Looney, K. M. Neuzil, J. F. Toney, C. A. Kauffman, S. K. Keay, A. R. Marques, C. T. Pachucki, M. J. Levin, K. E. Schmader, V. A. Morrison, P. F. Wright, M. R. Griffin, R. F. Betts, L. D. Gelb, J. Guatelli, D. J. Looney, K. M. Neuzil, B. Menzies, J. F. Toney

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

Background. The Shingles Prevention Study (SPS) demonstrated zoster vaccine efficacy through 4 years postvaccination. A Short-Term Persistence Substudy (STPS) demonstrated persistence of vaccine efficacy for at least 5 years. A Long-Term Persistence Substudy (LTPS) was undertaken to further assess vaccine efficacy in SPS vaccine recipients followed for up to 11 years postvaccination. Study outcomes were assessed for the entire LTPS period and for each year from 7 to 11 years postvaccination. Methods. Surveillance, case determination, and follow-up were comparable to those in SPS and STPS. Because SPS placebo recipients were offered zoster vaccine before the LTPS began, there were no unvaccinated controls. Instead, SPS and STPS placebo results were used to model reference placebo groups. Results. The LTPS enrolled 6867 SPS vaccine recipients. Compared to SPS, estimated vaccine efficacy in LTPS decreased from 61.1% to 37.3% for the herpes zoster (HZ) burden of illness (BOI), from 66.5% to 35.4% for incidence of postherpetic neuralgia, and from 51.3% to 21.1% for incidence of HZ, and declined for all 3 outcome measures from 7 through 11 years postvaccination. Vaccine efficacy for the HZ BOI was significantly greater than zero through year 10 postvaccination, whereas vaccine efficacy for incidence of HZ was significantly greater than zero only through year 8. Conclusions. Estimates of vaccine efficacy decreased over time in the LTPS population compared with modeled control estimates. Statistically significant vaccine efficacy for HZ BOI persisted into year 10 postvaccination, whereas statistically significant vaccine efficacy for incidence of HZ persisted only through year 8.

Original languageEnglish (US)
Pages (from-to)900-909
Number of pages10
JournalClinical Infectious Diseases
Volume60
Issue number6
DOIs
StatePublished - Jan 1 2015

Fingerprint

Herpes Zoster Vaccine
Herpes Zoster
Vaccines
Cost of Illness
Incidence
Placebos
Outcome Assessment (Health Care)
Postherpetic Neuralgia

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Morrison, V. A., Johnson, G. R., Schmader, K. E., Levin, M. J., Zhang, J. H., Looney, D. J., ... Toney, J. F. (2015). Long-term persistence of zoster vaccine efficacy. Clinical Infectious Diseases, 60(6), 900-909. https://doi.org/10.1093/cid/ciu918

Long-term persistence of zoster vaccine efficacy. / Morrison, Vicki A.; Johnson, Gary R.; Schmader, Kenneth E.; Levin, Myron J.; Zhang, Jane H.; Looney, David J.; Betts, Robert; Gelb, Larry; Guatelli, John C.; Harbecke, Ruth; Pachucki, Connie; Keay, Susan; Menzies, Barbara; Griffin, Marie R.; Kauffman, Carol A.; Marques, Adriana; Toney, John; Boardman, Kathy; Su, Shu Chih; Li, Xiaoming; Chan, Ivan S.F.; Parrino, Janie; Annunziato, Paula; Oxman, Michael N.; Davis, L. E.; Kauffman, C. A.; Keay, S. K.; Straus, S. E.; Marques, A. R.; Soto, N. E.; Brunell, P.; Gnann, J. W.; Serrao, R.; Cotton, D. J.; Goodman, R. P.; Arbeit, R. D.; Pachucki, C. T.; Levin, M. J.; Schmader, K. E.; Keitel, W. A.; Greenberg, R. N.; Morrison, V. A.; Wright, P. F.; Griffin, M. R.; Simberkoff, M. S.; Yeh, S. S.; Lobo, Z.; Holodniy, M.; Loutit, J.; Betts, R. F.; Gelb, L. D.; Crawford, G. E.; Guatelli, J.; Brooks, P. A.; Looney, D. J.; Neuzil, K. M.; Toney, J. F.; Kauffman, C. A.; Keay, S. K.; Marques, A. R.; Pachucki, C. T.; Levin, M. J.; Schmader, K. E.; Morrison, V. A.; Wright, P. F.; Griffin, M. R.; Betts, R. F.; Gelb, L. D.; Guatelli, J.; Looney, D. J.; Neuzil, K. M.; Menzies, B.; Toney, J. F.

In: Clinical Infectious Diseases, Vol. 60, No. 6, 01.01.2015, p. 900-909.

Research output: Contribution to journalArticle

Morrison, VA, Johnson, GR, Schmader, KE, Levin, MJ, Zhang, JH, Looney, DJ, Betts, R, Gelb, L, Guatelli, JC, Harbecke, R, Pachucki, C, Keay, S, Menzies, B, Griffin, MR, Kauffman, CA, Marques, A, Toney, J, Boardman, K, Su, SC, Li, X, Chan, ISF, Parrino, J, Annunziato, P, Oxman, MN, Davis, LE, Kauffman, CA, Keay, SK, Straus, SE, Marques, AR, Soto, NE, Brunell, P, Gnann, JW, Serrao, R, Cotton, DJ, Goodman, RP, Arbeit, RD, Pachucki, CT, Levin, MJ, Schmader, KE, Keitel, WA, Greenberg, RN, Morrison, VA, Wright, PF, Griffin, MR, Simberkoff, MS, Yeh, SS, Lobo, Z, Holodniy, M, Loutit, J, Betts, RF, Gelb, LD, Crawford, GE, Guatelli, J, Brooks, PA, Looney, DJ, Neuzil, KM, Toney, JF, Kauffman, CA, Keay, SK, Marques, AR, Pachucki, CT, Levin, MJ, Schmader, KE, Morrison, VA, Wright, PF, Griffin, MR, Betts, RF, Gelb, LD, Guatelli, J, Looney, DJ, Neuzil, KM, Menzies, B & Toney, JF 2015, 'Long-term persistence of zoster vaccine efficacy', Clinical Infectious Diseases, vol. 60, no. 6, pp. 900-909. https://doi.org/10.1093/cid/ciu918
Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ et al. Long-term persistence of zoster vaccine efficacy. Clinical Infectious Diseases. 2015 Jan 1;60(6):900-909. https://doi.org/10.1093/cid/ciu918
Morrison, Vicki A. ; Johnson, Gary R. ; Schmader, Kenneth E. ; Levin, Myron J. ; Zhang, Jane H. ; Looney, David J. ; Betts, Robert ; Gelb, Larry ; Guatelli, John C. ; Harbecke, Ruth ; Pachucki, Connie ; Keay, Susan ; Menzies, Barbara ; Griffin, Marie R. ; Kauffman, Carol A. ; Marques, Adriana ; Toney, John ; Boardman, Kathy ; Su, Shu Chih ; Li, Xiaoming ; Chan, Ivan S.F. ; Parrino, Janie ; Annunziato, Paula ; Oxman, Michael N. ; Davis, L. E. ; Kauffman, C. A. ; Keay, S. K. ; Straus, S. E. ; Marques, A. R. ; Soto, N. E. ; Brunell, P. ; Gnann, J. W. ; Serrao, R. ; Cotton, D. J. ; Goodman, R. P. ; Arbeit, R. D. ; Pachucki, C. T. ; Levin, M. J. ; Schmader, K. E. ; Keitel, W. A. ; Greenberg, R. N. ; Morrison, V. A. ; Wright, P. F. ; Griffin, M. R. ; Simberkoff, M. S. ; Yeh, S. S. ; Lobo, Z. ; Holodniy, M. ; Loutit, J. ; Betts, R. F. ; Gelb, L. D. ; Crawford, G. E. ; Guatelli, J. ; Brooks, P. A. ; Looney, D. J. ; Neuzil, K. M. ; Toney, J. F. ; Kauffman, C. A. ; Keay, S. K. ; Marques, A. R. ; Pachucki, C. T. ; Levin, M. J. ; Schmader, K. E. ; Morrison, V. A. ; Wright, P. F. ; Griffin, M. R. ; Betts, R. F. ; Gelb, L. D. ; Guatelli, J. ; Looney, D. J. ; Neuzil, K. M. ; Menzies, B. ; Toney, J. F. / Long-term persistence of zoster vaccine efficacy. In: Clinical Infectious Diseases. 2015 ; Vol. 60, No. 6. pp. 900-909.
@article{087e87eec0bb43cdaa40e8808a95a8da,
title = "Long-term persistence of zoster vaccine efficacy",
abstract = "Background. The Shingles Prevention Study (SPS) demonstrated zoster vaccine efficacy through 4 years postvaccination. A Short-Term Persistence Substudy (STPS) demonstrated persistence of vaccine efficacy for at least 5 years. A Long-Term Persistence Substudy (LTPS) was undertaken to further assess vaccine efficacy in SPS vaccine recipients followed for up to 11 years postvaccination. Study outcomes were assessed for the entire LTPS period and for each year from 7 to 11 years postvaccination. Methods. Surveillance, case determination, and follow-up were comparable to those in SPS and STPS. Because SPS placebo recipients were offered zoster vaccine before the LTPS began, there were no unvaccinated controls. Instead, SPS and STPS placebo results were used to model reference placebo groups. Results. The LTPS enrolled 6867 SPS vaccine recipients. Compared to SPS, estimated vaccine efficacy in LTPS decreased from 61.1{\%} to 37.3{\%} for the herpes zoster (HZ) burden of illness (BOI), from 66.5{\%} to 35.4{\%} for incidence of postherpetic neuralgia, and from 51.3{\%} to 21.1{\%} for incidence of HZ, and declined for all 3 outcome measures from 7 through 11 years postvaccination. Vaccine efficacy for the HZ BOI was significantly greater than zero through year 10 postvaccination, whereas vaccine efficacy for incidence of HZ was significantly greater than zero only through year 8. Conclusions. Estimates of vaccine efficacy decreased over time in the LTPS population compared with modeled control estimates. Statistically significant vaccine efficacy for HZ BOI persisted into year 10 postvaccination, whereas statistically significant vaccine efficacy for incidence of HZ persisted only through year 8.",
author = "Morrison, {Vicki A.} and Johnson, {Gary R.} and Schmader, {Kenneth E.} and Levin, {Myron J.} and Zhang, {Jane H.} and Looney, {David J.} and Robert Betts and Larry Gelb and Guatelli, {John C.} and Ruth Harbecke and Connie Pachucki and Susan Keay and Barbara Menzies and Griffin, {Marie R.} and Kauffman, {Carol A.} and Adriana Marques and John Toney and Kathy Boardman and Su, {Shu Chih} and Xiaoming Li and Chan, {Ivan S.F.} and Janie Parrino and Paula Annunziato and Oxman, {Michael N.} and Davis, {L. E.} and Kauffman, {C. A.} and Keay, {S. K.} and Straus, {S. E.} and Marques, {A. R.} and Soto, {N. E.} and P. Brunell and Gnann, {J. W.} and R. Serrao and Cotton, {D. J.} and Goodman, {R. P.} and Arbeit, {R. D.} and Pachucki, {C. T.} and Levin, {M. J.} and Schmader, {K. E.} and Keitel, {W. A.} and Greenberg, {R. N.} and Morrison, {V. A.} and Wright, {P. F.} and Griffin, {M. R.} and Simberkoff, {M. S.} and Yeh, {S. S.} and Z. Lobo and M. Holodniy and J. Loutit and Betts, {R. F.} and Gelb, {L. D.} and Crawford, {G. E.} and J. Guatelli and Brooks, {P. A.} and Looney, {D. J.} and Neuzil, {K. M.} and Toney, {J. F.} and Kauffman, {C. A.} and Keay, {S. K.} and Marques, {A. R.} and Pachucki, {C. T.} and Levin, {M. J.} and Schmader, {K. E.} and Morrison, {V. A.} and Wright, {P. F.} and Griffin, {M. R.} and Betts, {R. F.} and Gelb, {L. D.} and J. Guatelli and Looney, {D. J.} and Neuzil, {K. M.} and B. Menzies and Toney, {J. F.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1093/cid/ciu918",
language = "English (US)",
volume = "60",
pages = "900--909",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Long-term persistence of zoster vaccine efficacy

AU - Morrison, Vicki A.

AU - Johnson, Gary R.

AU - Schmader, Kenneth E.

AU - Levin, Myron J.

AU - Zhang, Jane H.

AU - Looney, David J.

AU - Betts, Robert

AU - Gelb, Larry

AU - Guatelli, John C.

AU - Harbecke, Ruth

AU - Pachucki, Connie

AU - Keay, Susan

AU - Menzies, Barbara

AU - Griffin, Marie R.

AU - Kauffman, Carol A.

AU - Marques, Adriana

AU - Toney, John

AU - Boardman, Kathy

AU - Su, Shu Chih

AU - Li, Xiaoming

AU - Chan, Ivan S.F.

AU - Parrino, Janie

AU - Annunziato, Paula

AU - Oxman, Michael N.

AU - Davis, L. E.

AU - Kauffman, C. A.

AU - Keay, S. K.

AU - Straus, S. E.

AU - Marques, A. R.

AU - Soto, N. E.

AU - Brunell, P.

AU - Gnann, J. W.

AU - Serrao, R.

AU - Cotton, D. J.

AU - Goodman, R. P.

AU - Arbeit, R. D.

AU - Pachucki, C. T.

AU - Levin, M. J.

AU - Schmader, K. E.

AU - Keitel, W. A.

AU - Greenberg, R. N.

AU - Morrison, V. A.

AU - Wright, P. F.

AU - Griffin, M. R.

AU - Simberkoff, M. S.

AU - Yeh, S. S.

AU - Lobo, Z.

AU - Holodniy, M.

AU - Loutit, J.

AU - Betts, R. F.

AU - Gelb, L. D.

AU - Crawford, G. E.

AU - Guatelli, J.

AU - Brooks, P. A.

AU - Looney, D. J.

AU - Neuzil, K. M.

AU - Toney, J. F.

AU - Kauffman, C. A.

AU - Keay, S. K.

AU - Marques, A. R.

AU - Pachucki, C. T.

AU - Levin, M. J.

AU - Schmader, K. E.

AU - Morrison, V. A.

AU - Wright, P. F.

AU - Griffin, M. R.

AU - Betts, R. F.

AU - Gelb, L. D.

AU - Guatelli, J.

AU - Looney, D. J.

AU - Neuzil, K. M.

AU - Menzies, B.

AU - Toney, J. F.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background. The Shingles Prevention Study (SPS) demonstrated zoster vaccine efficacy through 4 years postvaccination. A Short-Term Persistence Substudy (STPS) demonstrated persistence of vaccine efficacy for at least 5 years. A Long-Term Persistence Substudy (LTPS) was undertaken to further assess vaccine efficacy in SPS vaccine recipients followed for up to 11 years postvaccination. Study outcomes were assessed for the entire LTPS period and for each year from 7 to 11 years postvaccination. Methods. Surveillance, case determination, and follow-up were comparable to those in SPS and STPS. Because SPS placebo recipients were offered zoster vaccine before the LTPS began, there were no unvaccinated controls. Instead, SPS and STPS placebo results were used to model reference placebo groups. Results. The LTPS enrolled 6867 SPS vaccine recipients. Compared to SPS, estimated vaccine efficacy in LTPS decreased from 61.1% to 37.3% for the herpes zoster (HZ) burden of illness (BOI), from 66.5% to 35.4% for incidence of postherpetic neuralgia, and from 51.3% to 21.1% for incidence of HZ, and declined for all 3 outcome measures from 7 through 11 years postvaccination. Vaccine efficacy for the HZ BOI was significantly greater than zero through year 10 postvaccination, whereas vaccine efficacy for incidence of HZ was significantly greater than zero only through year 8. Conclusions. Estimates of vaccine efficacy decreased over time in the LTPS population compared with modeled control estimates. Statistically significant vaccine efficacy for HZ BOI persisted into year 10 postvaccination, whereas statistically significant vaccine efficacy for incidence of HZ persisted only through year 8.

AB - Background. The Shingles Prevention Study (SPS) demonstrated zoster vaccine efficacy through 4 years postvaccination. A Short-Term Persistence Substudy (STPS) demonstrated persistence of vaccine efficacy for at least 5 years. A Long-Term Persistence Substudy (LTPS) was undertaken to further assess vaccine efficacy in SPS vaccine recipients followed for up to 11 years postvaccination. Study outcomes were assessed for the entire LTPS period and for each year from 7 to 11 years postvaccination. Methods. Surveillance, case determination, and follow-up were comparable to those in SPS and STPS. Because SPS placebo recipients were offered zoster vaccine before the LTPS began, there were no unvaccinated controls. Instead, SPS and STPS placebo results were used to model reference placebo groups. Results. The LTPS enrolled 6867 SPS vaccine recipients. Compared to SPS, estimated vaccine efficacy in LTPS decreased from 61.1% to 37.3% for the herpes zoster (HZ) burden of illness (BOI), from 66.5% to 35.4% for incidence of postherpetic neuralgia, and from 51.3% to 21.1% for incidence of HZ, and declined for all 3 outcome measures from 7 through 11 years postvaccination. Vaccine efficacy for the HZ BOI was significantly greater than zero through year 10 postvaccination, whereas vaccine efficacy for incidence of HZ was significantly greater than zero only through year 8. Conclusions. Estimates of vaccine efficacy decreased over time in the LTPS population compared with modeled control estimates. Statistically significant vaccine efficacy for HZ BOI persisted into year 10 postvaccination, whereas statistically significant vaccine efficacy for incidence of HZ persisted only through year 8.

UR - http://www.scopus.com/inward/record.url?scp=84929884631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929884631&partnerID=8YFLogxK

U2 - 10.1093/cid/ciu918

DO - 10.1093/cid/ciu918

M3 - Article

VL - 60

SP - 900

EP - 909

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -